Versant Ventures

Versant Ventures, established in 1999, is a global healthcare investment firm headquartered in San Francisco, California. With over $2.3 billion under management and offices in North America and Europe, the firm invests across the healthcare sector, with a focus on discovering and developing novel therapeutics. Versant's team, comprising deep investment, operating, and scientific expertise, takes a hands-on approach to company building. Since inception, over 65 Versant companies have achieved successful acquisitions or IPOs.

Mehmet Badur

Principal

Bradley Bolzon

Managing Director

Jeremy Caldwell

Venture Partner

Samuel Colella

Co-Founder and Managing Director

Rich Van Doren

CFO

Joel Drewry

Principal

Peter Emtage

Venture Partner

Gianni Gromo

Partner

Katharina Kreymborg Ph.D

Principal

William Link

Co-Founder

Guido Magni

Partner

Don Milder

Co-Founder and Managing Director

Shane Mulligan

Principal

Kirk G. Nielsen

Managing Partner

Clare Ozawa

Managing Director

Nikita Sharma

Principal

Rami Hannoush Ph.D

Venture Partner

Past deals in Medical Devices

Granite Bio

Series A in 2025
Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Borealis Biosciences

Series A in 2024
Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

ViaLase

Series A in 2021
ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

Passage Bio

Series B in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Passage Bio

Series A in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Nuvaira

Series E in 2019
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Inari Medical

Series C in 2018
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Intuity Medical

Debt Financing in 2018
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Respicardia

Venture Round in 2017
Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Sebacia

Series D in 2017
Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

Monteris Medical

Series C in 2017
Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Ebb Therapeutics

Series B in 2017
Ebb Therapeutics, Inc. is a company specializing in the development of a regional cerebral thermal therapy (RCTT) device aimed at addressing insomnia and sleep disorders. It offers the Ebb Insomnia Therapy, which is a drug-free solution designed to help individuals improve their sleep quality. Founded in 2008 and originally known as Cereve, Inc., the company is headquartered in Pittsburgh, Pennsylvania. Ebb Therapeutics focuses on innovative therapeutic approaches to enhance sleep health without the reliance on pharmaceuticals.

Veran Medical Technologies

Venture Round in 2016
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Intuity Medical

Venture Round in 2016
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Rox Medical

Series E in 2016
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Benvenue Medical

Series F in 2016
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Veran Medical Technologies

Venture Round in 2015
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Inari Medical

Series B in 2015
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Sebacia

Series C in 2015
Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

NeuWave Medical

Series C in 2015
NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Twelve

Series C in 2015
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Zyga Technology

Series D in 2014
Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

Ivantis

Series B in 2014
Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Benvenue Medical

Series E in 2014
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Ceterix Orthopaedics

Series B in 2014
Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

Sequent Medical

Series D in 2014
Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Nuvaira

Series D in 2014
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Intuity Medical

Venture Round in 2014
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Inari Medical

Series A in 2013
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Nuvaira

Series C in 2013
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Glaukos

Series F in 2013
Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Glumetrics

Debt Financing in 2013
GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Minerva Surgical

Venture Round in 2012
Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

Flexion Therapeutics

Series B in 2012
Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.

Cerephex

Series A in 2012
Cerephex Corporation develops non-invasive treatment and diagnostic technologies for chronic centralized pain conditions, specifically focusing on fibromyalgia. The company's flagship product, NeuroPoint, is a point-of-care medical device utilizing proprietary RINCE technology, which employs noninvasive cortical electrostimulation to target and modulate brain function. This device aims to address the abnormal pain processing mechanisms associated with fibromyalgia. Cerephex is actively working towards obtaining FDA approval for NeuroPoint, enabling its use in clinical outpatient settings under physician supervision. Founded in 2012 and based in Los Altos, California, Cerephex was previously known as Great Lakes BioSciences.

Cotera

Venture Round in 2012
Cotera, Inc. specializes in the design and development of orthopedic implants aimed at treating knee osteoarthritis. Founded in 2011 and located in Menlo Park, California, the company has introduced innovative devices, including the Latella device, which is surgically attached to the femur to alleviate medial knee pain associated with osteoarthritis. This implant not only provides immediate relief but is also designed for easy removal, preserving future treatment options for patients. Cotera's focus is on improving the quality of life for individuals suffering from joint pain through advanced orthopedic solutions.

Nuvaira

Series B in 2012
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Rox Medical

Series D in 2012
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Intuity Medical

Venture Round in 2012
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Benvenue Medical

Series D in 2012
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Twelve

Venture Round in 2012
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Zyga Technology

Series C in 2012
Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

Glumetrics

Venture Round in 2012
GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Sequent Medical

Series C in 2012
Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

AcuFocus

Venture Round in 2011
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Realeve

Series C in 2011
Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Intuity Medical

Series D in 2011
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

WaveTec Vision

Series D in 2011
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Benvenue Medical

Series C in 2011
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Glaukos

Series E in 2011
Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

SpaceOAR

Debt Financing in 2011
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Nuvaira

Series A in 2010
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Respicardia

Series C in 2010
Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Sequent Medical

Series B in 2010
Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

The Foundry

Series A in 2010
The Foundry, LLC is a medical device incubator based in Menlo Park, California, established in 1998. Specializing in seed investments, it focuses on collaborating with inventors to transform innovative concepts into successful companies. The Foundry offers a robust platform that includes mentorship, a multi-disciplinary team of experienced professionals, and access to an extensive funding network. By actively engaging as directors, engineering consultants, or advisors, The Foundry supports its portfolio companies throughout the development process and regulatory approval, leveraging the expertise of veteran entrepreneurs and investors in the medical device industry to foster growth and success.

Intuity Medical

Series D in 2010
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Standard BioTools

Venture Round in 2009
Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

SpaceOAR

Series B in 2009
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Flexion Therapeutics

Series A in 2009
Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.

Nexis Vision

Series B in 2009
Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Realeve

Series B in 2009
Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Inogen

Series E in 2009
Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

NovaLign Orthopaedics

Series B in 2009
NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

LensX Lasers

Series B in 2009
LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

WaveTec Vision

Series C in 2009
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Acclarent

Venture Round in 2009
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

CELLutions Biosystems

Series B in 2008
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

Hotspur Technologies

Series A in 2008
Hotspur Technologies is a prominent developer of catheter-based technologies designed to restore blood flow in patients with obstructed vessels. The company specializes in creating innovative products that utilize unique technology to open blood vessels more effectively and with minimal invasiveness. Through its advancements, Hotspur Technologies aims to improve patient outcomes in the treatment of vascular obstructions.

Respicardia

Series B in 2008
Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Lutonix

Series B in 2008
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Microfabrica

Series B in 2008
Microfabrica Inc. designs and develops micro-scale additive manufacturing solutions, focusing on creating complex, micron-precision metal structures through its patented EFAB micro-fabrication technology. Founded in 1999 and headquartered in Van Nuys, California, the company specializes in producing minuscule surgical instruments, including biopsy forceps and tissue scaffolds that expand with cell growth. Its advanced manufacturing process enables the production of fully assembled micro-devices for industries such as aerospace, electronics, and medical devices, allowing customers to achieve significant improvements in functionality, performance, and cost-effectiveness. Microfabrica operates as a subsidiary of Technoprobe S.p.A. and has a secondary office in Santa Clara, California. The company has garnered support from various reputable venture capital and private investors.

Glaukos

Series D in 2008
Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Glumetrics

Series C in 2008
GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Cameron Health

Series E in 2008
Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Rox Medical

Series C in 2008
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

NOVASYS MEDICAL

Series D in 2008
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodelingâ„¢ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodelingâ„¢ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

SpaceOAR

Series A in 2008
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Spiration

Series G in 2008
Spiration, Inc., operating as Olympus Respiratory America, specializes in the development of medical devices aimed at treating air leaks and lung diseases. Founded in 1999 and headquartered in Redmond, Washington, the company focuses on innovative solutions for both acute and chronic lung conditions. One of its key products is the IBV valve system, a minimally invasive device designed to redirect airflow from diseased sections of the lung to healthier areas. This system is particularly beneficial for patients suffering from emphysema, prolonged air leaks, and other complications associated with damaged lungs. As of 2010, Spiration operates as a subsidiary of Olympus America Inc.

Inogen

Series E in 2008
Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Confirma

Series C in 2008
Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing. CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.

Benvenue Medical

Series B in 2008
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Nexis Vision

Series A in 2008
Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Ablation Frontiers

Series C in 2007
Ablation Frontiers, Inc. is a medical device company located in Carlsbad, California, focused on developing solutions for individuals with atrial fibrillation (AF) and other cardiac arrhythmias. The company offers a range of products, including mapping and ablation catheters, as well as radiofrequency generators and accessories, aimed at assisting healthcare professionals in effectively treating these conditions. In 2006, Ablation Frontiers received CE Mark certification to market its catheter system and GENiusâ„¢ Radiofrequency Generator in the European Union for treating supraventricular arrhythmias and atrioventricular node ablation. Currently, the company is conducting a clinical trial under a United States Food and Drug Administration investigational device exemption to seek approval for its catheter system to address permanent, long-standing, persistent, and chronic AF in the United States, where its products are not yet approved for marketing or sales.

CELLutions Biosystems

Series B in 2007
Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

WaveTec Vision

Series B in 2007
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Acclarent

Series C in 2007
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Trius Therapeutics

Series A in 2007
Trius Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative antibiotics aimed at treating life-threatening infections. The company has successfully completed two Phase 3 clinical trials for its lead product, Tedizolid Phosphate, a second-generation oxazolidinone designed for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). As bacterial resistance to existing antibiotics continues to rise, the need for new therapeutics to combat multi-drug resistant infections becomes increasingly urgent. Trius Therapeutics is led by a skilled management team with extensive experience in drug development and regulation, contributing to the company's efforts to address critical healthcare challenges posed by antibiotic resistance.

Inogen

Series D in 2007
Inogen is a medical technology company specializing in oxygen therapy solutions for patients with chronic respiratory conditions. The company designs and manufactures portable oxygen concentrators, with its flagship product being the Inogen One system, which offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen sells its products to home medical equipment providers and directly rents devices to patients, primarily generating its revenue in the United States. Additionally, the company distributes its products internationally through partnerships with large gas companies and home oxygen providers. Inogen's mission is to enhance the freedom and independence of oxygen therapy users by providing innovative and user-friendly products and services.

Vantage Oncology

Series D in 2007
Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

AcuFocus

Series D in 2007
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Calypso Medical

Series D in 2007
Calypso Medical Technologies, based in Seattle, is a privately held medical device company specializing in tumor localization technology. The company's proprietary system employs miniaturized implanted devices known as Beacon electromagnetic transponders to continuously and accurately track the location of tumors, enhancing the precision and management of radiation therapy delivery. This technology is particularly aimed at body-wide cancers that are commonly treated with radiation. Calypso's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, ensuring compliance with regulatory standards. The company has established strategic partnerships with leading organizations in the medical field, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical, to further its mission of improving cancer treatment outcomes.

Standard BioTools

Series E in 2007
Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Intersection Medical

Series B in 2006
Intersection Medical, Inc. is a company focused on the development and marketing of non-invasive medical devices aimed at assisting physicians in the treatment of patients with heart failure. Founded in 2006 and headquartered in Carlsbad, California, the company is also working on innovative technologies designed to enhance visibility into patient health status. These advancements aim to deliver actionable data for both patients and healthcare providers, ultimately improving the management of heart conditions.

Neurotech

Series B in 2006
Neurotech is a privately held biotechnology company focused on developing innovative therapies for chronic retinal diseases, addressing significant unmet medical needs in the ophthalmology market. The company has created a novel ocular implant that facilitates the continuous production of therapeutic proteins directly in the eye. This system is designed to help therapeutic cells survive in challenging conditions, thereby replacing or supporting the function of deteriorating target cells or tissues. By enhancing the treatment options available for eye diseases, Neurotech aims to improve the quality of life for patients suffering from these conditions.

Intuity Medical

Series C in 2006
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Vantage Oncology

Series C in 2006
Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Impedimed

Venture Round in 2006
Impedimed Limited is a medical software technology company based in Pinkenba, Australia, specializing in the development, manufacturing, and distribution of bioimpedance spectroscopy (BIS) devices and software services. The company offers a range of noninvasive devices, including SOZO, which is designed for detecting lymphedema and monitoring fluid status in heart failure patients, as well as SFB7, which analyzes body composition in healthy individuals. Additionally, ImpediMed provides ImpediVET, a BIS device tailored for veterinary applications. The company's products cater primarily to hospitals and clinics across Australia, North America, and other international markets. Founded in 1999, Impedimed is committed to advancing medical technology for clinical assessments and monitoring of fluid status and tissue composition, while also offering a cloud-based platform for managing patient data.

Rox Medical

Series B in 2006
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Cameron Health

Series D in 2006
Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.